{
    "clinical_study": {
        "@rank": "156281", 
        "arm_group": {
            "arm_group_label": "Iodine (124I) Girentuximab", 
            "arm_group_type": "Experimental", 
            "description": "Single infusion of radio labeled antibody: 30 mL will be infused using an infusion pump at a rate of 2mL/min over 15 minutes on study day 0."
        }, 
        "brief_summary": {
            "textblock": "Study WX-20-002 will confirm diagnostic efficacy and safety of a PET/CT scan using Iodine\n      (124I) Girentuximab performed during the diagnostic work-up in patients with indeterminate\n      cT1-renal masses."
        }, 
        "brief_title": "REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT", 
        "condition": [
            "Renal Cell Carcinoma", 
            "Kidney Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. \u226518 years of age.\n\n          2. Presence of indeterminate cT1 renal mass by screening CT with and without contrast or\n             MRI with and without contrast (MRI only if CT is contra-indicated).\n\n          3. Negative serum pregnancy test; to be performed on female patients of childbearing\n             potential within 24 hours prior to receiving investigational product.\n\n          4. Recovered from toxicity of any prior therapy to grade 1 or better.\n\n          5. Able to take oral medication (KI).\n\n          6. Written informed consent available.\n\n        Exclusion Criteria:\n\n          1. Renal mass known to be a metastasis of another primary tumor.\n\n          2. Known histology of renal mass (e.g. by biopsy).\n\n          3. Active non-renal malignancy requiring therapy during the time frame of individual\n             patient study participation.\n\n          4. Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to Iodine (124I)\n             Girentuximab infusion on Day 0 or continuing adverse effects (>grade 1) from such\n             therapy.\n\n          5. Exposure to murine proteins or chimeric antibodies within the last 5 years.\n\n          6. Intercurrent medical condition that may limit patient's study participation or\n             compliance.\n\n          7. History of autoimmune hepatitis.\n\n          8. Mental impairment that may compromise the ability to give informed consent and comply\n             with the requirements of the study.\n\n          9. Participation in any other clinical trial involving another investigational product\n             within 4 weeks prior to enrollment.\n\n         10. Women who are pregnant or breastfeeding.\n\n         11. Contraindication to KI intake (see package insert/Appendix VI).\n\n         12. Hyperthyroidism, or Grave's Disease.\n\n         13. Contraindication for PET/CT."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01762592", 
            "org_study_id": "WX/20-002"
        }, 
        "intervention": {
            "arm_group_label": "Iodine (124I) Girentuximab", 
            "intervention_name": "Iodine (124I) Girentuximab", 
            "intervention_type": "Drug", 
            "other_name": "124I-cG250"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Iodine", 
                "Cadexomer iodine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 17, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095-1721"
                    }, 
                    "name": "David Geffen School of Medicine, UCLA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01805"
                    }, 
                    "name": "Lahey Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27711"
                    }, 
                    "name": "Duke University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104-4283"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "MD Anderson"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses", 
        "overall_contact": {
            "email": "roman.bartz@wilex.com", 
            "last_name": "Roman Bartz, PhD", 
            "phone": "+49 (0)89-41 31 38", 
            "phone_ext": "52"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Sensitivity and specificity of Iodine (124I) Girentuximab PET/CT scans will be compared to the threshold value of 0.70 using a two-sided exact binomial test at level 0.05.", 
            "safety_issue": "No", 
            "time_frame": "PET/CT imaging of the kidneys will be performed 5 (\u00b11) days (Day 4, 5, or 6) after the Iodine (124I) Girentuximab infusion."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01762592"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Wilex", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wilex", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}